📚 Stock Market Glossary

A T-Cell Engager (TCE) is an engineered bispecific antibody therapeutic featuring two distinct antigen-binding arms.

One arm selectively latches onto a tumor-associated antigen (e.g., CD19, DLL3, EGFR, BCMA) on the cancer cell, while the second arm binds to the CD3 co-receptor on cytotoxic T cells, creating an artificial immunological synapse that commands the T cell to destroy the tumor.

• Bypassing Cancer Immune Evasion: Tumors evade normal immune surveillance. TCE forces direct physical engagement, inducing T cells to release lethal granzymes and perforins directly into the malignant cell.
• Off-The-Shelf Alternative to CAR-T: While autologous CAR-T therapies require multi-week, personalized ex-vivo genetic engineering costing $400,000+, TCE bispecific antibodies are mass-produced off-the-shelf biologics ready for immediate patient infusion.
• Expanding into Solid Tumors: TCE platforms are aggressively expanding beyond hematologic malignancies into massive solid tumor indications (e.g., small cell lung cancer, prostate, and breast cancer).

Managing Cytokine Release Syndrome (CRS) through step-up dosing and antibody affinity optimization is vital for FDA approvals. Monitor clinical-stage bispecific developers achieving superior Overall Response Rates (ORR) with manageable immune safety profiles.